[25] HAEMODYNAMIC EFFECTS OF LACTOTRIPEPTIDES FROM FERMENTATION BY LACTOBACILLUS HELVETICUS IN NORMOTENSIVE SUBJECTS AND PATIENTS WITH HIGH-NORMAL BLOOD PRESSURE: A RANDOMIZED, DOUBLE-BLIND, CROSS-OVER CLINICAL TRIAL

2009 ◽  
Vol 19 ◽  
pp. S7 ◽  
Author(s):  
A.F.G. Cicero ◽  
M. Rosticci ◽  
M. Veronesi ◽  
S. Bacchelli ◽  
E. Strocchi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Haemodynamic Effects ◽  
Lactobacillus Helveticus ◽  
Normal Blood ◽  
Normal Blood Pressure ◽  
Double Blind ◽  
Normotensive Subjects

scholarly journals Rice Bran Supplement Containing A Functional Substance, the Novel Peptide Leu-Arg-Ala, has Anti-Hypertensive Effects: A Double-Blind, Randomized, Placebo-Controlled Study

Nutrients ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 726
Author(s):  
Ogawa ◽  
Shobako ◽  
Fukuhara ◽  
Satoh ◽  
Kobayashi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Placebo Group ◽  
Adverse Events ◽  
Rice Bran ◽  
Test Group ◽  
Normal Blood ◽  
Controlled Study ◽  
The Novel ◽  
Normal Blood Pressure ◽  
Double Blind

The anti-hypertensive effect of processed rice bran (PRB) was recently reported, for which the novel peptide Leu-Arg-Ala (LRA) was identified as the functional substance. The purpose of this study was to assess the anti-hypertensive effects of a rice bran supplement containing PRB in individuals with high-normal blood pressure (systolic blood pressure (SBP): 130–139 mmHg and/or diastolic blood pressure (DBP): 85–89 mmHg) or grade 1 hypertension (SBP: 140–159 mmHg and/or DBP: 90–99 mmHg). One hundred individuals with high-normal blood pressure or grade 1 hypertension were recruited to participate in this double-blind, randomized, placebo-controlled study. Participants were randomly allocated to the placebo group (n = 50) or the test group (n = 50). Each group took four test tablets (43 μg LRA/day) or four placebo tablets daily. The decrease in blood pressure in the test group compared with the placebo group was the primary outcome. Adverse events were recorded and hematological/urinary parameters measured to determine the safety of the supplement, which was the secondary outcome. In total, 87 participants completed the study. The SBP of the test group at 12 weeks was significantly lower than that of the placebo group (p = 0.0497). No serious adverse events were observed. Daily consumption of a rice bran supplement containing PRB can safely improve mildly elevated blood pressure.

scholarly journals Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial

2020 ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Lifestyle Modification ◽  
Intervention Group ◽  
Normal Blood ◽  
Control Group ◽  
Efficacy And Safety ◽  
Normal Blood Pressure ◽  
Change In Mean ◽  
Acupoint Stimulation

Abstract Background: High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the efficacy and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design: This prospective, randomized and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 minutes, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12-week from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, physical activity, body mass index and waist circumference. Adverse events during the trial will be monitored. Discussion: This trial will explore the feasibility and provide potential evidence for the efficacy and safety of TEAS plus lifestyle modification for high-normal BP. The results of this study will be published in a peer-reviewed journal. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900024982. Registered on August 6, 2019.

scholarly journals Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial

2020 ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Lifestyle Modification ◽  
Pilot Trial ◽  
Intervention Group ◽  
Normal Blood ◽  
Control Group ◽  
Normal Blood Pressure ◽  
Randomized Controlled ◽  
Acupoint Stimulation

Abstract Background:High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the efficacy effectiveness and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design:This prospective, randomized and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 minutes, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12-week from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, physical activity, body mass index and waist circumference. Adverse events during the trial will be monitored.Discussion:This trial will explore the feasibility and provide potential evidence for the efficacy effectiveness and safety of TEAS plus lifestyle modification for high-normal BP. Furthermore, this pilot trial is being undertaken to determine the feasibility of a full scale definitive randomized controlled trial. The results of this study will be published in a peer-reviewed journal.Trial registration:Chinese Clinical Trial Registry, ChiCTR 1900024982. Registered on August 6, 2019.

Intralymphocytic Sodium in Hypertensive Patients: A Significant Correlation

1979 ◽  
Vol 57 (s5) ◽  
pp. 325s-327s ◽  
Author(s):  
E. Ambrosioni ◽  
F. Tartagni ◽  
L. Montebugnoli ◽  
B. Magnani
Keyword(s):  
Blood Pressure ◽  
Normal Subjects ◽  
Sodium Concentration ◽  
The Other ◽  
Mean Blood Pressure ◽  
Normal Blood ◽  
Normal Blood Pressure ◽  
Hypertensive Patients ◽  
Normotensive Subjects

1. Intralymphocytic sodium concentration was measured in 50 patients with essential stable hypertension, 44 patients with labile hypertension and 40 subjects with normal blood pressure. 2. Intralymphocytic sodium concentration in normotensive subjects was significantly lower than in the other two groups. 3. The concentration was significantly correlated with mean blood pressure in the group as a whole and in the groups with stable and with labile hypertension. No correlation was found in normal subjects.

scholarly journals Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Lifestyle Modification ◽  
Pilot Trial ◽  
Intervention Group ◽  
Normal Blood ◽  
Control Group ◽  
Normal Blood Pressure ◽  
Randomized Controlled ◽  
Acupoint Stimulation

Abstract Background High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the effectiveness and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design This prospective, randomized, and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 min, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12 weeks from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, body mass index, and waist circumference. Adverse events during the trial will be monitored. Discussion This trial will explore the feasibility and provide potential evidence for the effectiveness and safety of TEAS plus lifestyle modification for high-normal BP. Furthermore, this pilot trial is being undertaken to determine the feasibility of a full scale definitive randomized controlled trial. The results of this study will be published in a peer-reviewed journal. Trial registration Chinese Clinical Trial Registry, ChiCTR 1900024982. Registered on August 6, 2019.

scholarly journals Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial

2020 ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Lifestyle Modification ◽  
Pilot Trial ◽  
Intervention Group ◽  
Normal Blood ◽  
Control Group ◽  
Normal Blood Pressure ◽  
Randomized Controlled ◽  
Acupoint Stimulation

Abstract Background: High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the effectiveness and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design: This prospective, randomized and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 minutes, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12-week from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, physical activity, body mass index and waist circumference. Adverse events during the trial will be monitored.Discussion: This trial will explore the feasibility and provide potential evidence for the effectiveness and safety of TEAS plus lifestyle modification for high-normal BP. Furthermore, this pilot trial is being undertaken to determine the feasibility of a full scale definitive randomized controlled trial. The results of this study will be published in a peer-reviewed journal.Trial registration: Chinese Clinical Trial Registry, ChiCTR 1900024982. Registered on August 6, 2019.

Sign in / Sign up

Export Citation Format

Share Document